Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24414014 | 0.84 | ELANE (0.36) | ELANE | |
| SCHEMBL24414008 | 0.80 | ELANE (0.39) | ELANE | |
| SCHEMBL24413720 | 0.80 | PCNA (0.39) | ELANEARHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL24413636 | 0.80 | LPAR1 (0.43) | ELANEFFAR1L3MBTL1ARLPAR1 | |
| SCHEMBL24413648 | 0.78 | ELANE (0.40) | ELANETLR8ALDH1A1HSD17B10 | |
| SCHEMBL24413533 | 0.77 | ELANE (0.46) | ELANEL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24414033 | 0.77 | ELANE (0.44) | ELANETLR8ALDH1A1HSD17B10 | |
| SCHEMBL24413637 | 0.76 | HSD17B10 (0.44) | ELANEL3MBTL1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL24413518 | 0.76 | LMNA (0.35) | ELANELIPESMN1; SMN2 | |
| SCHEMBL24413638 | 0.76 | ELANE (0.40) | ELANEARTLR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220146930-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220146930-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | RER1, FGFR1, NHERF1 | ELANE 1517/4885FFAR1 33/4885L3MBTL1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.